222
Citations
112
Journals
2010
First Cited
2022
Last Cited

Articles citing This Document (Page 1 of 5)

ArticleJournalYear
Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States2022
Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
Reduced CXCR4 expression in associated with extramedullary and predicts poor survival in newly diagnosed multiple myeloma
Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma2022
Myeloma precursor disease (MGUS) among rescue and recovery workers exposed to the World Trade Center disaster2022
Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study2022
Safety and tolerability of lenalidomide maintenance dosing in patients with multiple myeloma post-autologous stem cell transplantJournal of Oncology Pharmacy Practice
Real-world treatment patterns for patients with newly diagnosed multiple myeloma in Alberta, CanadaLeukemia and Lymphoma
What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple MyelomaTargeted Oncology
Monoclonal gammopathy detection and current technologies2022
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myelomaBlood Reviews2022
Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patientsScientific Reports2022
Convenient Access to Expert-Reviewed Health Information via an Alexa Voice Assistant Skill for Patients With Multiple Myeloma: Development StudyJMIR Cancer2022
Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: a retro‐prospective observational studyEuropean Journal of Haematology
Converting a drug from off‐label to on‐label use: Government subsidies and patient welfareDecision Sciences
Melflufen for the treatment of multiple myelomaExpert Review of Clinical Pharmacology
Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myelomaJournal of Oncology Pharmacy Practice
Suprasellar Plasmacytoma Leading to the Diagnosis of Multiple MyelomaCureus2022
Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie’s choice for patients with relapsed refractory multiple myelomaExpert Review of Hematology
Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma.Future Oncology2022
Increasing genomic discovery in newly diagnosed multiple myeloma: defining disease biology and its correlation to risk.Annals of Hematology2022
Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, Including Triple-Class Exposure in the United States.Oncology and Therapy2022
Diagnostic Applications of Nuclear Medicine: Multiple Myeloma2022
Hematological Diseases2022
Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma.PLoS ONE2022
Demographic differences among patients treated with chimeric antigen receptor T-cell therapy in the United States.Cancer Medicine2022
Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies.Leukemia and Lymphoma2022
Host-microbe interactions and outcomes in multiple myeloma and hematopoietic stem cell transplantation.Cancer and Metastasis Reviews2022
Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis.Blood Cancer Journal2022
Data_Sheet_1.pdf2020
Long term survival in multiple myeloma: a single institution experience in underprivileged circumstances.Leukemia and Lymphoma2021
Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma.Supportive Care in Cancer2022
Therapy-related myeloid neoplasms following treatment for multiple myeloma-a single center analysis.Annals of Hematology2022
Case Report: Cavernous Sinus Syndrome as the Initial Presentation of Multiple Myeloma2022
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database.Clinical Lymphoma, Myeloma and Leukemia2022
Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs
A Review of Propylene Glycol-free Melphalan Conditioning for Hematopoietic Cell Transplantation for Multiple Myeloma and Light Chain Amyloidosis.Transplantation and Cellular Therapy2022
Myeloma-Related Hypercalcemia and Bone DiseaseContemporary Endocrinology2022
Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients.Leukemia2022
Incidence of corneal adverse events in patients with multiple myeloma and their clinical and economic impact: a real-world retrospective cohort study.Journal of Medical Economics2022
Management of Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Novel Combination Therapies in Routine Clinical Practice in Germany.Advances in Therapy2022
Utilization of CRISPR-Mediated Tools for Studying Functional Genomics in Hematological Malignancies: An Overview on the Current Perspectives, Challenges, and Clinical Implications.Frontiers in Genetics2021
The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.Journal of Oncology Pharmacy Practice2022
Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine.Nature Reviews Clinical Oncology2022
Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams.Frontiers in Oncology2021
An integrated approach to protein discovery and detection from complex biofluids
Isatuximab: Nursing Considerations for Use in the Treatment of Multiple MyelomaClinical Journal of Oncology Nursing2021
Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review studyBMC Cancer2021
Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myelomaJCI Insight2021
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patientsHematology, Transfusion and Cell Therapy2021